Complete scintigraphic lesion regression after single 153Sm- EDTMP therapy in prostate cancer

Revista Espanola de Medicina Nuclear

Volumn 20, Issue 4, 2001, Pages 311-312

  Weiss, K ^a   Kock H H ^a   Atefie, K ^a   Sinzinger, H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LEXIDRONAM SAMARIUM SM 153; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; SAMARIUM; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

ARTICLE; BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; HUMAN; MALE; ORCHIECTOMY; PALLIATIVE THERAPY; PROSTATE CANCER; REMISSION; ADENOCARCINOMA; BONE TUMOR; CASE REPORT; METASTASIS; MIDDLE AGED; PROSTATE TUMOR; SCINTISCANNING;

ADENOCARCINOMA; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REMISSION INDUCTION; SAMARIUM;

EID: 0035382836     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S0212-6982(01)71965-9     Document Type: Article

References (3)

1. 89strontium and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
2. 186Rhenium HEDP. Palliative radionuclide therapy of painful bone metastases. Preliminary results. Scand J Urol Nephrol 1997;31:445-8.
3. 153-samarium ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989;7:1926-31.